Abstract
In Reply. —The primary objective of the trial described in our article was to determine the benefit of combination treatment with zidovudine and lamivudine relative to zidovudine monotherapy on changes in CD4 cell counts and measures of HIV-1 viral load. The trial was not statistically powered to detect differences between treatment arms in progression to CDC category C (acquired immunodeficiency syndrome) events or death. However, the lower rate of clinical progression in the combination therapy arms in the trial is consistent with the results of a meta-analysis of trials of zidovudine combined with lamivudine that showed a 66% reduction in progression to CDC category C events, 1 and in the recently reported CAESAR trial of combined zidovudine and lamivudine, which has shown a 54% reduction in progression to CDC category C/death end points for patients adding lamivudine to zidovudine-containing regimens. 2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
